Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome

Siddika E Karakas, Rogelio U. Almario, Laura Gregory, Rodney Wong, Heather Todd, Bill L. Lasley

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Effects of a polyunsaturated fatty acid (PUFA)-rich diet were investigated in 17 polycystic ovary syndrome (PCOS) patients. After a 3-month habitual diet period, dietary fats were partly replaced with PUFAs for another 3 months. The PUFA-rich diet increased plasma linoleic acid from 28.36 ± 1.00% to 33. 76 ± 1.08% (P < 0.002) and α-linolenic acid from 0.52 ± 0.03% to 1.06 ± 0.10% (P < 0.0001). Fasting glucose increased from 76 ± 3 to 95 ± 3 mg/dl (4.2 ± 0.2 to 5.30.2 mmol/liter; P < 0.0001), and the area under the curve for glucose during oral glucose tolerance test increased from 421 ± 34 to 503 ± 31 mg/dl (23.4 ± 1.9 to 27.9 ± 1.7 mmol/liter; P < 0.001). Plasma insulin did not change either at fasting or during oral glucose tolerance test. Fasting plasma free fatty acids decreased from 0.596 ± 0.048 to 0.446 ± 0.058 mg/dl (P = 0.037), and ketone bodies decreased from 9.14 ± 1.57 to 3.63 ± 0.62 mg/dl (895 ± 154 to 356 ± 61 μmol/liter; P < 0.003). Plasma 15-deoxyprostaglandin J2 tended to decrease (from 239 ± 65 to 171 ± 60 ng/ml; P = 0.053). Plasma testosterone, free testosterone, SHBG, dehydroepiandrosterone sulfate, LH, FSH, and urinary estrogen conjugates did not change. Urinary pregnanediol 3-glucuronide increased from 18.6 ± 2.2 to 31.0 ± 5.7 μg/mg creatinine (P = 0.038). In conclusion, increased dietary PUFA intake can exert significant metabolic and endocrine effects in women with PCOS.

Original languageEnglish (US)
Pages (from-to)615-620
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Polycystic Ovary Syndrome
Nutrition
Unsaturated Fatty Acids
Diet
Plasmas
Glucose
Fasting
Glucose Tolerance Test
Testosterone
Ketone Bodies
Dehydroepiandrosterone Sulfate
alpha-Linolenic Acid
Dietary Fats
Linoleic Acid
Nonesterified Fatty Acids
Area Under Curve
Creatinine
Estrogens
Insulin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome. / Karakas, Siddika E; Almario, Rogelio U.; Gregory, Laura; Wong, Rodney; Todd, Heather; Lasley, Bill L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 2, 02.2004, p. 615-620.

Research output: Contribution to journalArticle

Karakas, Siddika E ; Almario, Rogelio U. ; Gregory, Laura ; Wong, Rodney ; Todd, Heather ; Lasley, Bill L. / Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 2. pp. 615-620.
@article{ea242e22d76e414c91b91ce58aad1080,
title = "Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome",
abstract = "Effects of a polyunsaturated fatty acid (PUFA)-rich diet were investigated in 17 polycystic ovary syndrome (PCOS) patients. After a 3-month habitual diet period, dietary fats were partly replaced with PUFAs for another 3 months. The PUFA-rich diet increased plasma linoleic acid from 28.36 ± 1.00{\%} to 33. 76 ± 1.08{\%} (P < 0.002) and α-linolenic acid from 0.52 ± 0.03{\%} to 1.06 ± 0.10{\%} (P < 0.0001). Fasting glucose increased from 76 ± 3 to 95 ± 3 mg/dl (4.2 ± 0.2 to 5.30.2 mmol/liter; P < 0.0001), and the area under the curve for glucose during oral glucose tolerance test increased from 421 ± 34 to 503 ± 31 mg/dl (23.4 ± 1.9 to 27.9 ± 1.7 mmol/liter; P < 0.001). Plasma insulin did not change either at fasting or during oral glucose tolerance test. Fasting plasma free fatty acids decreased from 0.596 ± 0.048 to 0.446 ± 0.058 mg/dl (P = 0.037), and ketone bodies decreased from 9.14 ± 1.57 to 3.63 ± 0.62 mg/dl (895 ± 154 to 356 ± 61 μmol/liter; P < 0.003). Plasma 15-deoxyprostaglandin J2 tended to decrease (from 239 ± 65 to 171 ± 60 ng/ml; P = 0.053). Plasma testosterone, free testosterone, SHBG, dehydroepiandrosterone sulfate, LH, FSH, and urinary estrogen conjugates did not change. Urinary pregnanediol 3-glucuronide increased from 18.6 ± 2.2 to 31.0 ± 5.7 μg/mg creatinine (P = 0.038). In conclusion, increased dietary PUFA intake can exert significant metabolic and endocrine effects in women with PCOS.",
author = "Karakas, {Siddika E} and Almario, {Rogelio U.} and Laura Gregory and Rodney Wong and Heather Todd and Lasley, {Bill L.}",
year = "2004",
month = "2",
doi = "10.1210/jc.2003-030666",
language = "English (US)",
volume = "89",
pages = "615--620",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Metabolic and Endocrine Effects of a Polyunsaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome

AU - Karakas, Siddika E

AU - Almario, Rogelio U.

AU - Gregory, Laura

AU - Wong, Rodney

AU - Todd, Heather

AU - Lasley, Bill L.

PY - 2004/2

Y1 - 2004/2

N2 - Effects of a polyunsaturated fatty acid (PUFA)-rich diet were investigated in 17 polycystic ovary syndrome (PCOS) patients. After a 3-month habitual diet period, dietary fats were partly replaced with PUFAs for another 3 months. The PUFA-rich diet increased plasma linoleic acid from 28.36 ± 1.00% to 33. 76 ± 1.08% (P < 0.002) and α-linolenic acid from 0.52 ± 0.03% to 1.06 ± 0.10% (P < 0.0001). Fasting glucose increased from 76 ± 3 to 95 ± 3 mg/dl (4.2 ± 0.2 to 5.30.2 mmol/liter; P < 0.0001), and the area under the curve for glucose during oral glucose tolerance test increased from 421 ± 34 to 503 ± 31 mg/dl (23.4 ± 1.9 to 27.9 ± 1.7 mmol/liter; P < 0.001). Plasma insulin did not change either at fasting or during oral glucose tolerance test. Fasting plasma free fatty acids decreased from 0.596 ± 0.048 to 0.446 ± 0.058 mg/dl (P = 0.037), and ketone bodies decreased from 9.14 ± 1.57 to 3.63 ± 0.62 mg/dl (895 ± 154 to 356 ± 61 μmol/liter; P < 0.003). Plasma 15-deoxyprostaglandin J2 tended to decrease (from 239 ± 65 to 171 ± 60 ng/ml; P = 0.053). Plasma testosterone, free testosterone, SHBG, dehydroepiandrosterone sulfate, LH, FSH, and urinary estrogen conjugates did not change. Urinary pregnanediol 3-glucuronide increased from 18.6 ± 2.2 to 31.0 ± 5.7 μg/mg creatinine (P = 0.038). In conclusion, increased dietary PUFA intake can exert significant metabolic and endocrine effects in women with PCOS.

AB - Effects of a polyunsaturated fatty acid (PUFA)-rich diet were investigated in 17 polycystic ovary syndrome (PCOS) patients. After a 3-month habitual diet period, dietary fats were partly replaced with PUFAs for another 3 months. The PUFA-rich diet increased plasma linoleic acid from 28.36 ± 1.00% to 33. 76 ± 1.08% (P < 0.002) and α-linolenic acid from 0.52 ± 0.03% to 1.06 ± 0.10% (P < 0.0001). Fasting glucose increased from 76 ± 3 to 95 ± 3 mg/dl (4.2 ± 0.2 to 5.30.2 mmol/liter; P < 0.0001), and the area under the curve for glucose during oral glucose tolerance test increased from 421 ± 34 to 503 ± 31 mg/dl (23.4 ± 1.9 to 27.9 ± 1.7 mmol/liter; P < 0.001). Plasma insulin did not change either at fasting or during oral glucose tolerance test. Fasting plasma free fatty acids decreased from 0.596 ± 0.048 to 0.446 ± 0.058 mg/dl (P = 0.037), and ketone bodies decreased from 9.14 ± 1.57 to 3.63 ± 0.62 mg/dl (895 ± 154 to 356 ± 61 μmol/liter; P < 0.003). Plasma 15-deoxyprostaglandin J2 tended to decrease (from 239 ± 65 to 171 ± 60 ng/ml; P = 0.053). Plasma testosterone, free testosterone, SHBG, dehydroepiandrosterone sulfate, LH, FSH, and urinary estrogen conjugates did not change. Urinary pregnanediol 3-glucuronide increased from 18.6 ± 2.2 to 31.0 ± 5.7 μg/mg creatinine (P = 0.038). In conclusion, increased dietary PUFA intake can exert significant metabolic and endocrine effects in women with PCOS.

UR - http://www.scopus.com/inward/record.url?scp=1442327811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442327811&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-030666

DO - 10.1210/jc.2003-030666

M3 - Article

C2 - 14764771

AN - SCOPUS:1442327811

VL - 89

SP - 615

EP - 620

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -